Alterations of ß-tubulin isotypes in breast cancer cells resistant to docetaxel Kawan Shalli * , Iain Brown * , Steven D. Heys * and Andrew C. Schofield * ,† ,1 Schools of * Medicine and † Medical Sciences, College of Life Sciences and Medicine, University of Aberdeen, Medical School, Foresterhill, Aberdeen, UK 1 Correspondence: School of Medicine, College of Life Sciences and Medicine, University of Aberdeen, Medical School, Foresterhill, Aberdeen, AB25 2ZD, UK. E-mail: a.schofield@abdn.ac.uk <h3>SPECIFIC AIMS</h3> Docetaxel is one of the most active drugs used to treat breast cancer and its cellular target is the microtubule, specifically the ß-tubulin subunit that comprises a series of isotypes and can modulate function. This study has examined the alterations in ß-tubulin isotypes (mRNA and proteins) in vitro and has sequenced the ß-tubulin gene to determine whether there were mutations, both of which may represent important mechanisms of acquired resistance to docetaxel in breast cancer cells. <h3>PRINCIPAL FINDINGS</h3> <h3>1. Differential expression of mRNA ß-tubulin isotypes in docetaxel-resistant estrogen receptor-positive and estrogen receptor-negative breast cancer cells</h3> Human breast cancer cell lines MCF-7 (estrogen receptor-positive) and MDA-MB-231 (estrogen receptor-negative) were made resistant to docetaxel by short-term in vitro exposure to docetaxel. MCF-7 docetaxel-resistant
/lp/fed-of-american-socs-for-experimental-biology/alterations-of-tubulin-isotypes-in-breast-cancer-cells-resistant-to-Lr0wXVlJvD